Overview
Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.
Eligibility
Inclusion Criteria:
- Subjects who fully understood this trial and voluntarily signed the informed consent form;
- Men or women ≥ 18 years old;
- ECOG Performance Status (PS) 0 or 1;
- Life expectancy > 3 months.
Exclusion Criteria:
- Received any treatment with inhibitors against KRAS G12C mutation at any time, e.g., AMG 510, MRTX 849, etc.;
- Patients requiring medications that can potentially prolong QTc interval;
- Other conditions that the investigator considers to be unsuitable for participation in this study.